Network meta-analysis of survival data with fractional polynomials

被引:129
作者
Jansen, Jeroen P. [1 ]
机构
[1] Mapi Values, Boston, MA USA
关键词
CELL LUNG-CANCER; PHASE-III TRIAL; GEFITINIB IRESSA; DOCETAXEL; INCONSISTENCY; MODELS;
D O I
10.1186/1471-2288-11-61
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Pairwise meta-analysis, indirect treatment comparisons and network meta-analysis for aggregate level survival data are often based on the reported hazard ratio, which relies on the proportional hazards assumption. This assumption is implausible when hazard functions intersect, and can have a huge impact on decisions based on comparisons of expected survival, such as cost-effectiveness analysis. Methods: As an alternative to network meta-analysis of survival data in which the treatment effect is represented by the constant hazard ratio, a multi-dimensional treatment effect approach is presented. With fractional polynomials the hazard functions of interventions compared in a randomized controlled trial are modeled, and the difference between the parameters of these fractional polynomials within a trial are synthesized (and indirectly compared) across studies. Results: The proposed models are illustrated with an analysis of survival data in non-small-cell lung cancer. Fixed and random effects first and second order fractional polynomials were evaluated. Conclusion: (Network) meta-analysis of survival data with models where the treatment effect is represented with several parameters using fractional polynomials can be more closely fitted to the available data than meta-analysis based on the constant hazard ratio.
引用
收藏
页数:14
相关论文
共 29 条
[1]   Bayesian methods for evidence synthesis in cost-effectiveness analysis [J].
Ades, AE ;
Sculpher, M ;
Sutton, A ;
Abrams, K ;
Cooper, N ;
Welton, N ;
Lu, GB .
PHARMACOECONOMICS, 2006, 24 (01) :1-19
[2]  
Akaike H., 1973, 2 INT S INFORM THEOR, P267
[3]   Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality [J].
Bagnardi, V ;
Zambon, A ;
Quatto, P ;
Corrao, G .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (11) :1077-1086
[4]   Dynamic Cox modelling based on fractional polynomials:: time-variations in gastric cancer prognosis [J].
Berger, U ;
Schäfer, J ;
Ulm, K .
STATISTICS IN MEDICINE, 2003, 22 (07) :1163-1180
[5]   Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer [J].
Bossard, N ;
Descotes, F ;
Bremond, AG ;
Bobin, Y ;
De Saint Hilarie, P ;
Golfier, F ;
Awada, A ;
Mathevet, PM ;
Berrerd, L ;
Barbier, Y ;
Estève, J .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (01) :47-59
[6]   Simultaneous comparison of multiple treatments: combining direct and indirect evidence [J].
Caldwell, DM ;
Ades, AE ;
Higgins, JPT .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7521) :897-900
[7]   Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].
Chang, Alex ;
Parikh, Purvish ;
Thongprasert, Sumitra ;
Tan, Eng Huat ;
Perng, Reury- Perng ;
Ganzon, Domingo ;
Yang, Chih-Hsin ;
Tsao, Chao-Jung ;
Watkins, Claire ;
Botwood, Nick ;
Thatcher, Nick .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855
[8]   Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation [J].
Cooper, Nicola J. ;
Sutton, Alex J. ;
Morris, Danielle ;
Ades, A. E. ;
Welton, Nicky J. .
STATISTICS IN MEDICINE, 2009, 28 (14) :1861-1881
[9]   Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer [J].
Cufer, Tania ;
Vrdoljak, Eduard ;
Gaafar, Rabab ;
Erensoy, Inci ;
Pemberton, Kristine .
ANTI-CANCER DRUGS, 2006, 17 (04) :401-409
[10]   Platinum-Based Second-Line Treatment in Non-Small-Cell Lung Cancer: An Old New Kid on the Block? [J].
de Lima Araujo, Luiz Henrique ;
Ferreira, Carlos G. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :E24-E25